Quell® Fibromyalgia showed sequential revenue growth with significant gains in unique prescribers and prescriptions, demonstrating success in its flagship pain management product. The company's Quell® technology received FDA Breakthrough Designation for reducing moderate to severe symptoms of chemotherapy induced peripheral neuropathy. Prior to acquisition, the company was transitioning to a leaner operational model with reduced expenses.
Cyborg Score Rationale
Q1 2024 revenue was $1.1 million, down 37% from Q1 2023, with gross margin declining to 47% and operating expenses rising to $3.8 million, resulting in a net loss of $3.0 million. The company faced significant financial headwinds and liquidity constraints prior to its acquisition.
Top Insights
(May 2025) Acquired by electroCore, ending independent public trading
FDA Breakthrough Designation for Quell® in chemotherapy-induced peripheral neuropathy treatment
Strong product momentum in Quell Fibromyalgia but declining overall revenue and significant operating losses
Focused on managing capital structure and reducing operating expenses prior to acquisition
Named Competitors
ReliefBand — Wearable bioelectronic medicine for pain and nausea
Nevro — Spinal cord stimulation for chronic pain
Bioness — Functional electrical stimulation for muscle rehabilitation
Recent Developments
(December 2024) Announced definitive merger agreement with electroCore
(March 2025) NeuroMetrix shareholders approved merger with electroCore
(May 2025) electroCore completed acquisition of NeuroMetrix
Open the full interactive NeuroMetrix, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.